The new unit represents an investment of $30 million and will allow the company to boost its capacity to produce COVID-19 vaccines and other therapies, it said. The new unit will add more than 350 new jobs and 18,300 sq ft of space. It will produce Mobius single-use assemblies, and will be in operation by the end of the year, according to the firm.

MilliporeSigma is accelerating its European expansion plans for single-use assembly technology, which is used for the production of Covid-19 vaccines and other lifesaving therapies. Image courtesy of MilliporeSigma.

MilliporeSigma is expanding its capacity at its facilities in Darmstadt, Germany; Cork, Ireland; Buchs, Switzerland; Carlsbad, CA; Madison, WI; Jaffrey, NH; and Danvers, MA. At the Danvers site, the company is working to double single-use production capacity by the end of 2021, it said.

MilliporeSigma acquires AmpTec
MilliporeSigma has purchased messenger RNA firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture messenger RNA...

MilliporeSigma invests $47M in U.S. biomanufacturing facilities
MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing...

MilliporeSigma holds topping-out ceremony for new membrane plant
MilliporeSigma celebrated the topping out of its new membrane production plant in Darmstadt, Germany, with a ceremony on October 8.

MilliporeSigma expands antibody-drug conjugate manufacturing
MilliporeSigma is expanding its high-potent active pharmaceutical ingredient and antibody-drug conjugate manufacturing capabilities with a $65 million...

MIT, MilliporeSigma create Pandemic Response CoLab
The Massachusetts Institute of Technology (MIT) has launched Pandemic Response CoLab with the goal of bringing together innovators from around the globe...